Print this article
P. 40-42 /

Clinical development of the toll-like receptor 9 agonist DIMS0150 in chronic active ulcerative colitis patients

THOMAS KNITTEL

Chief Medical Officer, InDex Pharmaceuticals AB

KEYWORDS: Toll-like receptors, ulcerative colitis, therapy, oligonucleotide.

ULCERATVE COLITIS

Ulcerative colitis (UC) is an immune-mediated condition characterized by a continuous mucosal inflammation of the colon, which might be caused from the dysregulated balance between commensal enteric flora and the gut-associated immune system. A proportion of patients do not respond to available therapies becoming treatment refractory and requiring surgical intervention and therefore novel treatment strategies are needed (1-3).
One of the ways that host discerns foreign from self-antigen is through pattern recognition receptors (PRRs), which recognize specific molecular patterns of pathogens. One g